Skip to Content

Jakafi Approval History

Jakafi (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of patients with myelofibrosis and polycythemia vera.

Development History and FDA Approval Process for Jakafi

Dec  4, 2014Approval FDA Approves Jakafi (ruxolitinib) for Polycythemia Vera
Nov 16, 2011Approval FDA Approves Jakafi to Treat Myelofibrosis
Aug  3, 2011FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
Jun  8, 2011Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.